Browse treatments

…cific products. To circumvent these challenges and limitations, in situ immunotherapy administers immunostimulatory adjuvants directly into tumors, w…

…ltration, MCC tumors often evade immune-mediated killing. While anti-PD-1/PD-L1 therapies are efficacious, MCC patients resistant or relapsing after immu…

…omarkers predictive of the likelihood of patients responding to adjuvant immunotherapies. Briefly, we applied cell segmentation and unbiased cell typing…

…e PD1+ CXCL13+ T helper and TCF7+ progenitor CD8+ T cells after immune checkpoint blockade, suggesting interactions between these cells can overcome T cel…

…r metastatic MTC. In the setting of progressive metastatic MTC, TKIs (selpercatinib, cabozantinib and vandetanib) can prolong surviv…

…Background Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as an advanced and highly effective approach for tr…

…s than 50% of patients with advanced pancreatic cancer tolerate combination chemotherapy. Combining immune-mediated cytotoxicity with payload-mediated c…

…ndomised controlled trial will enrol 424 parturients undergoing epidural analgesia for trial of labour. Participants will be randomised (1:1) to r…

…100 mg two times per day). Twenty-seven (87%) patients received immunomodulatory treatment at the time of PPF.Conclusions In our cohort, the underlying di…

…piratory support (continuous positive airway pressure (CPAP) or non-invasive ventilation) to aid airway clearance. 1 2 Published evidence is sparse.1 2 …

… in MOGS CDG (congenital disorder of glycosylation type IIb). A mannose-based diet led to partial improvement. This case highlights the importance…

…action than CSII users (p=0.044) and lower diabetes burden than MDI users (p=0.044) after controlling for age and gender. Treatment…